Citeline：2025年可能上市的主要药物展望报告（英文版）

Dermavant’s Vtama (tapinarof) is a non-steroidal topical agent that targets the aryl hydrocarbon receptor. Approved for the treatment of psoriasis in the US in May 2022, Vtama has shown comparable efficacy to Zoryve, although it has been linked to side effects such as folliculitis and contact dermatitis. In February 2024, Dermavant submitted a supplemental NDA to the FDA for Vtama cream, aiming to treat atopic dermatitis in adults and children aged two years and older, supported by promising